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Abstract
Measurement of both calprotectin and lactoferrin in faeces has successfully been used to discriminate between functional
and inflammatory bowel conditions, but evidence is limited for Clostridium difficile infection (CDI). We prospectively
recruited a cohort of 164 CDI cases and 52 controls with antibiotic-associated diarrhoea (AAD). Information on disease
severity, duration of symptoms, 30-day mortality and 90-day recurrence as markers of complicated CDI were recorded.
Specimens were subject to microbiological culture and PCR-ribotyping. Levels of faecal calprotectin (FC) and lactoferrin (FL)
were measured by ELISA. Statistical analysis was conducted using percentile categorisation. ROC curve analysis was
employed to determine optimal cut-off values. Both markers were highly correlated with each other (r2 = 0.74) and elevated
in cases compared to controls (p,0.0001; ROC.0.85), although we observed a large amount of variability across both
groups. The optimal case-control cut-off point was 148 mg/kg for FC and 8.1 ng/ml for FL. Median values for FL in CDI cases
were significantly greater in patients suffering from severe disease compared to non-severe disease (104.6 vs. 40.1 ng/ml,
p = 0.02), but were not significant for FC (969.3 vs. 512.7 mg/kg, p = 0.09). Neither marker was associated with 90-day
recurrence, prolonged CDI symptoms, positive culture results and colonisation by ribotype 027. Both FC and FL
distinguished between CDI cases and AAD controls. Although FL was associated with disease severity in CDI patients, this
showed high inter-individual variability and was an isolated finding. Thus, FC and FL are unlikely to be useful as biomarkers
of complicated CDI disease.
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Introduction
Clostridium difficile infection (CDI) is a major cause of
nosocomial infections in patients undergoing antimicrobial treat-
ment and is subject to mandatory notification in the UK [1–3]. It
accounts for approximately 20% of antibiotic-associated diarrhoea
cases. CDI pathogenesis is attributed to the action of two potent
toxins, A and B [4,5]. Their synergistic effects cause fluid
accumulation and damage to the epithelial mucosa [6], further
eliciting pro-inflammatory cytokine release [7,8]. Concurrent
activation and recruitment of neutrophils results in an inflamma-
tory response in the gastrointestinal tract of CDI patients, but this
is variable, ranging from self-contained mild inflammation to
severe pseudomembranous colitis [9,10].
Toxins are the essential virulence factors accounting for CDI
pathogenicity. Current diagnostic tools rely on their detection by
either cytotoxin neutralisation or enzyme immunoassays. Multi-
step algorithms have also been adopted in an attempt to improve
sensitivity by combining toxin detection with sensitive screening of
the presence of the organism by selective culture, glutamate
dehydrogenase antigen (GDH) detection and/or nucleic acid
amplification tests (NAAT) of the locus of pathogenicity (PaLoc)
[11]. These tests do not allow for stratification of disease severity
and prognosis in patients with CDI. Validated non-invasive enteric
markers for CDI that allow for better patient assessment and
enable a more personalised approach to treatment would be
valuable [11].
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Table 1. Overview of previous studies evaluating the role of lactoferrin and calprotectin in faeces in patients with Clostridium
difficile infection.
Study Country
Healthcare
setting Paticipants Measure used Results
Associated
outcomes (p-value)
Faecal Lactoferrin
Steiner et al.
(1997)30
USA Hospital Mild CDI (n = 6) Qualitative (positive/
negative)
1/6 = positive Disease severity*
(P = 0.021)
Severe CDI (n = 12) 9/12 = positive
Vaishnavi et al.
(2000)27
India Hospital CDI cases (n = 41) Qualitative (positive/
negative)
33/41 = positive C. diff toxin positivity &
negativity (P,0.001 for
both)
Diarrhoea controls
(n = 190)
123/190 = negative
Pawlowski et al.
(2009)31
USA Hospital CDI cases (n = 34) Cut-off (72.5 mg/g) 10 resistant =.72.5 mg/g Moxifloxacin resistance
(P = 0.041)
16 resistant =,72.5 mg/g
8 susceptible =,72.5 mg/g
Archbald-
Pannone et al.
(2010)26
USA LTCF CDI cases (n = 2) Continuous 134.1 mg/ml C. diff colonisation
(P = 0.008)
Diarrhoea controls
(n = 22)
28.8 mg/ml
Van Langenberg
et al. (2010)20
Australia Hospital CDI cases (n = 8) Continuous 33.3 mg/ml C. diff positivity
(P = 0.017)
Diarrhoea controls
(n = 334)
22.6 mg/ml
El Feghaly et al.
(2013)28
USA Hospital CDI cases (n = 120) Cut-off (7.25 mg/ml) 72/120 (60%) =.7.25 mg/ml
(Outcome data not provided)
Severe HINES VA
Score** (P = 0.002)
Boone et al.
(2013)29
USA Hospital &
outpatients
Mild CDI (n = 7) Continuous 73 mg/g Disease severity*** and
Ribotype 027
(P = 0.0003 & P= 0.012)
Moderate CDI (n = 57) 292 mg/g
Severe CDI (n = 21) 961 mg/g
LaSala et al.
(2013)25
USA Hospital GDH neg (n = 43) Continuous 13 mg/ml Toxin positivity vs.
GDH negative;
p = 0.006
GDH positive/Tox
neg/PCR neg (n = 14)
18 mg/ml Toxin positivity vs.
GDH positive/CDT
negative/PCR negative;
p = 0.002
GDH positive/Tox
neg/PCR positive
(n = 30)
80 mg/ml Toxin positivity vs.
GHD positive/CDT
negative/PCR positive;
p = 0.015
GDH positive/Tox
positive (n = 25)
24 mg/ml -
Shastri et al.
(2008)23
Germany Hospital CDI cases (n = 87) Continuous 192 mg/l -
Healthy controls
(n = 200)
171/196 =,15 mg/l
Whitehead et al.
(2014)24
UK Hospital Tox positive (n = 45) Continuous 336 mg g-1 C. diff positivity (P,
0.05)
GDH positive/PCR
positive (n = 75)
249 mg g-1
Diarrhoea controls
(n = 99)
106 mg g-1
*Disease was considered severe if any of the following was present: diarrhoea severe enough to produce clinical signs of volume depletion and to require hospitalization, WBC
count of .10,000/ml, or temperature of .38.3uC.
**Scoring system accounting for fever (.38uC), ileus (clinical or radiographic), systolic blood pressure (,100 mmHg), WBC (15000,WBC,30000 cells/ml) and CT scan findings
(colonic wall thickening, colonic dilatation, ascites).
***Automatically classified as severe if age $65 years, WBC.156109/L, stool $10 per day, not able to tolerate oral intake, usually abdominal complaints, radiographic or
peritoneal signs, multiple comorbidities including but not limited to renal failure and immunosuppression.
doi:10.1371/journal.pone.0106118.t001
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Faecal material represents a very complex and heterogeneous
biological matrix. Candidate faecal biomarkers must possess
properties that ensure reliability and reproducibility of results
and they must be unaffected by extra-digestive processes. Faecal
calprotectin (FC) and faecal lactoferrin (FL), derived predomi-
nantly from activated neutrophils have both been extensively
evaluated in inflammatory bowel disease (IBD) and infectious
diarrhoea [12–22].
FC and FL have also been evaluated in CDI in a small number
of studies (Table 1). Some have shown an association of FC in
several acute diarrhoeal diseases caused by bacteria, with the
highest mean levels observed in patients with CDI (192 mg/L)
[23]. Others have shown a significant association when comparing
FC levels in toxin positive and GDH positive plus tcdA/tcdB PCR
confirmed patients when compared to diarrhoea controls [24].
Similarly, FL has also been shown to be elevated in CDI patients
[20,25–27], with more recent studies suggesting a positive
correlation with disease severity [28–30] and fluoroquinolone
resistance [31]. There are however limitations with the published
studies: these include their retrospective nature, limited phenotype
data, lack of matched controls, use of non-quantitative tests, and
variations in the assessment of CDI outcome measures. Sample
sizes have varied from 2 to 87, and none of the studies have
compared FC and FL in the same patient groups. In this study, we
use a prospective design, a carefully phenotyped cohort and
simultaneous evaluation of both faecal markers, to investigate
whether these faecal biomarkers would have clinical value in
patients with CDI.
Methods
Cohort
A cohort of 216 patients was recruited from a large hospital
setting in Merseyside, UK. Consecutive patients with healthcare-
associated diarrhoea, which was defined as $3 liquid stools passed
per day in the 24 hours preceding assessment, an onset after being
in hospital for over 48 hours and recent exposure to either
antimicrobials and/or proton pump inhibitors, were eligible for
inclusion. Relevant information on demographics, admission and
clinical evaluation was collected for each patient who consented to
participate and recorded into an anonymised case report
proforma.
Blood and faecal specimens were collected from patients at
study entry. Faecal samples were analysed by Clostridium difficile
toxin (CDT) testing using a commercial TOX A/B II ELISA kit
(Techlab, Blacksburg, USA) and selective anaerobic culture for
48 h using Brazier’s cefoxitin-cycloserine egg yolk agar (CCEY)
(Lab M Ltd, Bury, UK). Isolates were identified by characteristic
smell, colonial morphology and fluorescence under long wave UV
light. Identification was confirmed using a latex agglutination test
for C. difficile somatic antigen (Oxoid, Basingstoke, UK). Isolates
were stored on PROTECT beads (Technical Services Consultants
Ltd, Heywood, UK) at 270uC. PCR ribotyping of isolates was
performed using a standard method [32] and compared to a
library of circulating nosocomial strains [33]. A multiplex PCR
assay targeting a species-specific internal fragment of the triose
phosphate isomerase (tpi) housekeeping gene, internal core
sequences of both toxins A (tcdA) and B (tcdB) genes was used
to confirm all isolates as C. difficile and verify their individual
toxigenicity [34]. The initial diagnosis of CDI was made by the
responsible clinical teams, and the research team only became
involved when a diagnosis had been confirmed by a C. difficile
toxin positive ELISA result. Using these criteria, there were 164
CDI cases. Control patients (n = 52) were individuals with
evidence of antibiotic-associated diarrhoea (AAD), negative toxin
ELISA test and microbiological culture, with no past history of
CDI.
The severity of CDI symptoms was assessed at baseline by
research nurses as per guidelines proposed by Public Health
England – this is based on white blood cell count (.156109/L),
acutely rising blood creatinine (.50% increase above baseline),
fever (temperature .38.5uC), evidence of severe colitis (abdominal
signs, radiology) and further complications such as hypotension,
partial/complete ileus, toxic megacolon and colectomy [35]. We
Table 2. Demographics of the patient cohort.
CDI Cases (n =164) AAD Controls (n=52) P-value*
Patient’s characteristics
Gender – Female n (%) 95 (58) 35 (67) 0.26
Age – Mean in years (SD) 70.2 (15.9) 66.4 (15.8) 0.13
BMI – Mean (SD) 24.6 (6.4) 28.2 (6.9) ,0.01
Charlson Comorbidity Score** – Median (IQR) 1.0 (0.0–2.0) 1.0 (0.0–2.0) 0.22
Time delay prior to recruitment, days – Median (IQR) 3.0 (2.0–4.8) 2.0 (2.0–3.0) ,0.01
Clinical Parameters
All cause death within 30 days – n (%) 14/164 (8.5) 1/52 (1.9) 0.13
Duration of symptoms - 10 days and over – n (%) 83/145a (57.2) 12/46a (26.1) ,0.01
Severity at baseline – n (%) 48/164 (29.3) - -
Recurrence within 90 days – n (%) 53/116b (45.7) - -
Frequency of ribotype 027– n (%) 72/149c (48.3) - -
n: number; CDI: Clostridium difficile infection; AAD: Antibiotic-associated diarrhoea; BMI: Body mass index; IQR: Interquartile range; SD: Standard deviation;
*Means for normally distributed, continuous variables were compared using Independent samples T-test for continuous, for non-normal distribution median values were
compared using Mann Whitney U test. Categorical data was assessed using a Chi-squared test for all counts .5, and Fisher’s Exact test for those ,5;
**Charlson comorbidity score is calculated without accounting for age (see statistical methods);
aData regarding duration of symptoms was unavailable for 19 of our cases and 6 of our controls;
bData regarding recurrence of disease within 90 days was unavailable for 48 of our cases;
cIsolates were successfully recovered from 149/164 cases and thus ribotyping could not be done in 15 of our cases.
doi:10.1371/journal.pone.0106118.t002
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have further adjusted the white blood cell count to a more
stringent cut-off of .206109/L. Duration of symptoms from the
diarrhoea start date was recorded and then dichotomised into
episodes lasting more or less than 10 days, while mortality was
actively monitored for a period of 30 days. Recurrent CDI was
defined as the development of subsequent CDI episodes up to a
period of 90 days following treatment of the initial episode. These
different parameters collectively represent complicated CDI
disease.
Ethics statement
Ethical approval for the study was obtained from the Liverpool
Research Ethics Committee under reference numbers 08/H1005/
32 and each patient provided written informed consent prior to
recruitment.
Biomarker measurement in stools
Both FC and FL levels were measured using commercially
available IVD ELISA kits (Calpro, Lysaker, Norway; IBD Scan
Techlab, Blacksburg, USA, respectively). All procedures were
carried out according to manufacturer’s instructions, with the
exception of the FL sample preparation step, whereby an
inoculation loop was used as an agitator during a 30 minute
shaking step in order to ensure optimal recovery of proteins.
Where necessary, further dilutions and extra points on the
standard curve were included. A standard 4-parameter logistic
nonlinear regression method was used to calculate faecal
biomarker concentrations.
Statistical analysis
Levels of FC and FL were subject to a 4-tier percentile
categorization (i.e. Low ,25%, Medium 25–50%, High 50–75%
and Very High .75%). Univariate binary logistic regression was
conducted for both case-control comparison and sub-group
analysis of cases for the outcomes proposed above. Covariates
including age, gender, BMI, score on Charlson Comorbidity
Index, presence of ribotype 027 and time delay between testing
positive and subsequent recruitment were assessed. As age was
already included as an individual covariate, we calculated our
Charlson Comorbidity Index unadjusted for age, consistent with
Table 3. Faecal lactoferrin levels in Clostridium difficile infection (CDI) cases versus Antibiotic-associated diarrhoea (AAD) controls.
Faecal lactoferrin (ng/ul) CDI Cases (n=164) AAD Controls (n =52)
Median (IQR) 57.9 (11.4–177.5) 2.7 (0.7–7.8)
Range (Min. – Max.) 1,838.5 (0.5–1,839.0) 203.4 (0.1–203.5)
Percentile distribution CDI Cases (n=164) AAD Controls (n =52) Adjusted P-value* Adjusted OR (95% CI)
Low (Comparator group) 20 33 N/A N/A
Medium 41 14 ,0.0001 5.03 (2.05–12.34)
High 51 3 ,0.0001 31.67 (8.14–123.26)
Very high 52 2 ,0.0001 41.57 (8.55–202.10)
Global p-value ,161025
CDI: Clostridium difficile infection; AAD: Antibiotic-associated diarrhoea; n: number; IQR: Interquartile range; Min.: Minimum; Max.: Maximum; OR: Odds ratios; CI: Confidence
interval; N/A: Not applicable.
*P-value was calculated using binary logistic regression with data grouped into percentiles. Analysis was adjusted for significant covariates BMI and time delay between
testing positive and subsequent recruitment.
doi:10.1371/journal.pone.0106118.t003
Table 4. Faecal calprotectin levels in Clostridium difficile infection (CDI) cases versus Antibiotic-associated diarrhoea (AAD)
controls.
Faecal calprotectin (mg/kg) CDI Cases (n =159) AAD Controls (n=51)
Median (IQR) 684.8 (203.7–1,581.0) 66.5 (23.1–145.7)
Range (Min – Max) 21,440.5 (9.7–21,450.2) 1,807.8 (3.1–1,811)
Percentile distribution CDI Cases (n =159) AAD Controls (n=51) Adjusted P-value* Adjusted OR (95% CI)
Low (Comparator group) 21 31 N/A N/A
Medium 38 15 0.02 3.03 (1.21–7.53)
High 49 4 ,0.0001 21.82 (6.13–77.71)
Very high 51 1 ,0.0001 85.87 (10.21–721.90)
Global p-value ,161025
CDI: Clostridium difficile infection; AAD: Antibiotic-associated diarrhoea; n: number; IQR: Interquartile range; Min.: Minimum; Max.: Maximum; OR: Odds ratios; CI: Confidence
interval; N/A: Not applicable.
*P-value was calculated using binary logistic regression with data grouped into percentiles. Analysis was adjusted for significant covariates BMI, score on Charlson
Comorbidity Index (exclusive of age) and time delay between testing positive & subsequent recruitment.
doi:10.1371/journal.pone.0106118.t004
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previous studies [36–38], in order to avoid introducing an
undesirable level of collinearity into our analysis. Statistically
significant covariates were added to the final regression model to
produce adjusted p-values and ORs. A p-value of ,0.05 was
considered significant. Power calculations were simulated using
nQuery Advisor + nTerim 2.0 (Statistical Solutions Ltd., Cork,
Ireland).
ROC curve analysis was conducted to identify optimal cut-off
values for our cohort and to compare these against the
recommended kit values established for active intestinal inflam-
mation. The Pearson correlation coefficient was employed to
assess the relationship between the faecal markers.
Results
Demographics
Demographics of the patient cohort are summarised in Table 2.
No significant differences were observed between CDI cases and
AAD controls for mean age (70.2 yrs versus 66.4 yrs; P = 0.13),
gender (58% female versus 67% female, respectively; P = 0.26) or
median Charlson Comorbidity Index score (1.0 versus 1.0;
P = 0.22). However, significant differences were identified for
mean BMI (24.6 versus 28.2; P,0.01) and the median time delay
between testing positive and subsequent recruitment (3.0 days
versus 2.0 days; P,0.01). C. difficile isolates were successfully
recovered from 149 (91%) of the CDI cases, of which all were
toxigenic and 72 (48%) had the ribotype 027/NAP1.
The proportion of patients suffering from symptoms of 10 or
more days was higher amongst CDI cases compared with controls
(57.2% versus 26.1%, p,0.01). Of the CDI cases, 29.3% (48/164)
were assessed as having severe disease, while 46% (53/116) of
cases experienced recurrent episodes during the 3-month follow-
up period.
Power calculations
For both biomarkers, power to detect a significant difference
was calculated as $97% for the majority of analyses (Table S1).
However, for analysis of 30-day mortality for both FL and FC and
prolonged symptoms for FL, we had inadequate power.
Faecal concentrations of FC and FL in CDI
Median levels of both FL and FC were significantly higher in
CDI cases compared to AAD controls (Tables 3 & 4). This was
confirmed by percentile case-control analysis [Tables 3 & 4; p-
value,0.0001 for both]. ROC case-control analysis of FL resulted
in a cut-off value of 8.1 ng/ml with an AUC of 0.86 (95% CI 0.80–
0.92), producing a sensitivity of 81.7% (95% CI 75.8–87.6%),
specificity of 76.9% (65.4–88.4%), positive predictive value (PPV)
of 91.8% (87.3–96.3%) and negative predictive value (NPV) of
57.1% (45.5–68.7%) [Figure 1]. This result is similar to the
recommended kit cut-off point (7.25 ng/ml). For FC our optimal
cut-off value differed from that proposed by the manufacturer
(148 mg/kg versus 50mg/kg, respectively), suggesting that FC
levels are elevated in the AAD group. ROC analysis resulted in an
AUC of 0.86 (0.81–0.92), producing sensitivity of 81.8% (75.8–
87.8%), specificity of 76.5% (64.9–88.1%), whilst PPV and NPV
were 91.5% (86.9–96.1%) and 57.4% (45.6–69.2%), respectively
(Figure 1). There was a high degree of correlation between FC and
FL (r2 = 0.74) consistent across all patients groups [Figure S1].
Figure 1. ROC curve analyses of Faecal Lactoferrin and Faecal Calprotectin concentrations in Clostridium difficile infection cases
(n=164) versus Antibiotic-associated diarrhoea controls (n =52).
doi:10.1371/journal.pone.0106118.g001
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Sub-group percentile analysis identified that FL but not FC
correlated with severe disease (FL: 104.6 vs. 40.1 ng/ml, p = 0.02;
FC: 969.3 vs. 512.7 mg/kg, p = 0.09) [Figure 2; for FC please see
Figure S2]. There was considerable overlap for FL levels between
patients with severe and non-severe disease (Figure 2). For
duration of symptoms, a significant association was observed with
FC only when extreme percentiles were compared (p = 0.02), but
this was not significant when all percentiles were included
(p = 0.08). No significant associations were identified with the
other outcome measures [Figure 2; for FC please see Figure S2].
Carriers of the ribotype 027 generally displayed higher levels of
both faecal markers (median 1011 vs. 658 mg/kg, p = 0.09 for FC;
median 83.2 versus 51.0 ng/ml, p = 0.57 for FL), but this was not
significant. Median (range) levels of both FC and FL were higher
in culture positive compared with culture negative samples but not
significantly (712.2 (9.7–6,415.4) versus 345.8 (22.9–21,450.2) mg/
kg, p = 0.46 for FC; 63.5 (0.5–1,839.0) vs. 31.7 (2.6–318.5) ng/ml,
p = 0.22 for FL). Median levels of both FC and FL were however
significantly higher in culture negative patients compared to AAD
controls (345.8 versus 66.5 mg/kg, p,0.01 for FC; 31.7 versus
2.7 ng/ml, p,0.001 for FL).
Discussion
FC and FL are derived from neutrophils in faecal material, and
have been shown to correlate with the degree of inflammation in
diseases such as IBD. Since CDI is also characterised histologically
by intense neutrophilic infiltration [39], FC and FL may represent
potential biomarkers of disease activity. Using a prospective cohort
of inpatient CDI cases and AAD controls, we confirmed previous
findings that both FC and FL increase during CDI (p,0.0001)
[20,23,24,26,27]. There was a high degree of correlation between
the two biomarkers, not surprising given their cellular origin. No
previous CDI studies have evaluated both faecal biomarkers in the
same patient group. These findings are consistent with those seen
in IBD [12,13,15–18,21].
There are more studies on FL than FC for CDI (Table 1) but
only a few have provided quantitative data. For FL, the reported
mean/median values for CDI cases have differed markedly across
studies (33–961 mg/ml; Table 1) [20,25,26,29]. Our median value
is at the lower end of this range (57.9 ng/ml). By contrast, our
observed median level for FC was markedly higher than that in the
two previous CDI studies (648.8 mg/kg versus 192 and 249–
336 mg/kg) [23,24]. The median levels in our AAD controls were
Figure 2. Boxplots for faecal lactoferrin concentrations in relation to Clostridium difficile infection outcomes. i) Severity at baseline
(AUC=0.60); ii) Prolonged symptoms (AUC= 0.56); iii) 30-day mortality (AUC= 0.53); and iv) 90-day recurrence (AUC= 0.55). Faecal lactoferrin was
measured in 164 CDI cases. Data regarding duration of symptoms and disease recurrence was unavailable for 19 and 48 cases, respectively.
doi:10.1371/journal.pone.0106118.g002
Faecal Biomarkers in Patients with Clostridium difficile Infection
PLOS ONE | www.plosone.org 6 August 2014 | Volume 9 | Issue 8 | e106118
lower for both FL and FC (2.7 ng/ml versus 22.6–22.8 mg/ml and
66.5 mg/kg versus 106 mg/g, respectively; Table 1) than reported
previously in the two FL studies and one FC study that included
diarrhoea controls in their analysis [20,24,26]. Another study
showed that 171 of 196 healthy controls (87%) had an FC level less
than 15 mg/l [23], a similar observation to that seen in our AAD
controls (41/51; 80%). Considerable variability was observed in
different patients with CDI, which is consistent with data from
IBD studies for both FL (4.34–179 mg/ml) [13,16–18,21,40] and
FC (164–2171 mg/kg) [13,14,16,17,19,22,40–43].
While our data show that FC and FL can differentiate between
CDI and AAD, the use of these biomarkers for diagnosis per se
would not add much value to the diagnostic paradigms currently
in place. However, identification of patients with complicated CDI
disease (for example disease leading to more prolonged symptoms
and recurrent disease) would be useful. Our results show an
association between FL levels and disease severity (p = 0.02) but
not with FC (p = 0.09). This is an isolated finding, which taken
together with the fact that there was a great deal of variability in
actual concentrations, with significant overlap between the two
groups (Figure 2), limits its clinical applicability. Furthermore, we
observed no association with the other outcome measures
evaluated. It is important to note that we had adequate statistical
power to detect all of these outcomes except for 30-day mortality
and FL and prolonged symptoms (Table S1).
Direct comparisons between this and other studies are limited
by variability in methodologies adopted, the lack of quantitative
data, and differences in the severity grading criteria [28–30].
Another problem may result from the potential short-lived
characteristics of the biomarkers, which may hamper the
predictive power of these markers unless they are captured within
specific timeframes. A longitudinal study of FL [44] suggested that
FL could be used to monitor disease activity and response since FL
tends to return to baseline very rapidly following remission
[29,44].
Our study has limitations. Firstly, we only used a single
laboratory test (ELISA for CDT) for the primary identification of
CDI cases. Although this is still a common procedure, modern
algorithms currently make use of a more sensitive first step
screening - based on either GDH, or NAAT - to minimise the odds
of reporting false negative results. Therefore it is possible that our
cohort may have lacked a fully representative range of cases.
Furthermore, our AAD controls were not a homogenous group of
patients and it is difficult to assess their fitness for this sort of
analysis given that antimicrobials and/or PPIs may not be the sole
underlying cause of their gastrointestinal tract dysbiosis.
Nevertheless, our data highlight the difficulties in using FL and
FC as biomarkers for CDI. The variability observed would reduce
predictive accuracy, and cannot be completely ascribed to
variations in disease severity. Part of the variability may be due
to differences in laboratory methodology. The volume of diluent
for specimen suspension, and laboratory handling can each
influence results, and caution should be exercised in the
interpretation of single results [45]. Although serial testing may
have some value, it would add to the cost, and may be challenging
in diseases such as CDI, thus further reducing its utility.
Furthermore, these biomarkers can be elevated due to other
diseases [45], and this is particularly important for CDI where
infected patients are usually elderly with multiple co-morbidities.
There are no guidelines concerning the use of faecal biomarkers
for the classification of CDI cases. In IBD research, where faecal
biomarkers constitute a potential non-invasive alternative to
colonoscopy, the most recent diagnostics guidance by UK
National Institute for Health and Care Excellence (NICE) [46]
still recommends that further research is needed on the use and
clinical utility of faecal marker testing. Biomarkers which can act
as indicators of disease, disease relapse and disease stratification,
are also needed to direct CDI therapies more effectively. Our
results suggest that FC and FL have limited applicability in this
role.
Supporting Information
Figure S1 Correlation plot of Faecal Lactoferrin and
Faecal Calprotectin concentrations in all patients (cases
and controls combined; n=210).
(TIF)
Figure S2 Boxplots for faecal calprotectin concentra-
tions in relation to Clostridium difficile infection
outcomes. i) Severity at baseline (AUC = 0.59); ii) Prolonged
symptoms (AUC = 0.58); iii) 30-day mortality (AUC = 0.49); and
iv) 90-day recurrence (AUC = 0.58). Faecal calprotectin was
measured in 159 CDI cases. Data regarding duration of symptoms
and disease recurrence was unavailable for 18 and 47 cases,
respectively.
(TIF)
Table S1 Assessment of power across Clostridium
difficile infection outcome analyses. a: To achieve 80%
power we would require 749 patients in both sample groups. b: To
achieve 80% power we would require 1370 patients in both sample
groups. c: To achieve 80% power we would require 167 patients in
both sample groups.
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